Perjeta's Lower Market Potential Hits Our Roche FVE, but Shares Remain Compelling Value
Roche has exited the annual meeting of the American Society of Clinical Oncology with a mix of data, which we think was dominated by disappointing Aphinity data (breast cancer) but also included excellent (albeit expected) Alecensa data in lung cancer and early data as well as hints to a long-term strategy in immuno-oncology. We think the details on Perjeta’s efficacy in adjuvant breast cancer from the Aphinity study have a material impact on the firm's value and are likely to limit Perjeta's up...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.